CSL Ltd. Stock News

Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co. Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co.

SUMMIT, N.J. , Feb. 25, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the renewal of a five-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). 1 The agreement further strengthens the U.S. government''s pandemic preparedness and response capability by ensuring ready production of medical countermeasures (MCMs). This allows BARDA to request that Seqirus provide influenza vaccines and adjuvants for pre-pandemic stockpiling or for manufacture to support rapid response to an influenza pandemic or other public health emergency. Seqirus and BARDA have held similar agreements since 2006. Seqirus stands ready to provide BARDA with: Supply of AUDENZ™ (Influenza A(H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvanted, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic. 2 The vaccine combines Seqirus'' proprietary MF59 ® adjuvant technology with its cell-based manufacturing platform.

CSL Limited (CSLLY) CEO Paul Perreault on Q2 2022 Results - Earnings Call Transcript

CSL Limited press release (OTCPK:CSLLY): 1H GAAP EPS of $3.85.Revenue of $6.04B (+5.2% Y/Y).

Shares of CSL Limited (OTCMKTS:CSLLY) have been assigned a consensus recommendation of Hold from the eight research firms that are covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating and one has given a buy rating to the company. A number of research analysts have recently issued []

CSL (OTCMKTS: CSLLY) recently received a number of ratings updates from brokerages and research firms: 12/14/2021 CSL was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein []

CSL Limited (OTCMKTS:CSLLY) Equities research analysts at Jefferies Financial Group decreased their FY2022 EPS estimates for shares of CSL in a research note issued on Tuesday, December 14th. Jefferies Financial Group analyst D. Stanton now forecasts that the company will post earnings per share of $2.46 for the year, down from their prior forecast []

We examine ASX updates from PointsBet Holdings Ltd [ASX:PBH], Vulcan Energy Resources Ltd [ASX:VUL], and CSL Ltd [ASX:CSL]. The post ASX 200 News: Vulcan, PointsBet, and CSL Updates appeared first on Money Morning Australia .

Australian shares recovered from early falls to close flat on Tuesday, as gains in financials countered losses in retailers, while investors braced for a slew of central bank meetings this week, including by the US Federal Reserve. The S&P/ASX 200 index settled 0.01% lower at 7,378.40, clawing back from a 0.5% fall in early trade. Financials rose 0.2%, turning around from a 0.5% early fall, with three of the big four banks climbing between 0.04% and 0.6%. Commonwealth Bank of Australia slipped 0.5%. Retailers were the biggest losers on the benchmark, falling as much as 6% in their worst session since March 2020. The plunge came after Woolworths Group, Australia''s biggest supermarket chain, forecast lower first-half operating income from its domestic food business. Shares of Woolworths dived 7.7%, while those of rival Coles fell 2.7%. Miners climbed 0.6% as iron ore prices remained strong amid tight supply. Rio Tinto, BHP Group and Fortescue Metals rose between 0.05% and 1.4%. The Fed begins its two-day monetary policy meeting later in the day, and it is expected to announce a wrapping up of its bond buying stimulus sooner than previously communicated, potentially setting up earlier interest rate hikes next year.

Australian biopharmaceutical giant CSL Ltd said it would buy Swiss drugmaker Vifor Pharma AG for $11.7 billion, as it aims to diversify beyond its blood plasma collection business after taking a hit from COVID-19 curbs.

(RTTNews) - Today''s Daily Dose brings you news about the clinical hold imposed by the FDA on Merck''s trials; CSL Limited evincing interest for a Swiss based biotech, Atara''s ALLELE trial results, FDA approval of Veru''s ENTADFI and the Leukemia & Lymphoma Society''s findings regarding the need for a third primary dose of mRNA COVID-19 vaccine for…

CANBERA (dpa-AFX) - Australian biotech company CSL Ltd. (CSL.AX, CMXHF.PK) announced Tuesday its definitive agreement to acquire Swiss drugmaker Vifor Pharma Ltd. for an aggregate equity value of …

Agreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US$179.25 per share Offer equivalent to CHF167 per share1 Proposed ordinary divid…

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, today announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CH